400 Technology Square, 10th Floor
About Kymera Therapeutics
Despite recent advances in modern medicine, hundreds of millions of people are affected by acute and chronic diseases with limited or no available treatment options. Kymera is pioneering a game-changing new therapeutic modality with the potential to transform drug discovery and provide breakthrough treatments for previously untreatable diseases.
Co-Founder & Chairman: Bruce Booth, D. Phil.
Co-Founder & CTO: Nello Mainolfi, Ph.D.
President & CEO: Laurent Audoly, Ph.D.
Please click here for Kymera's technology.:
15 articles with Kymera Therapeutics
Kymera Therapeutics to Present Preclinical Data Demonstrating the Potency and Antitumor Activity of a Selective STAT3 Degrader at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Kymera Therapeutics Inc. announced the company will present preclinical data showing the discovery and characterization of novel, selective, and potent degraders of STAT3, a transcriptional regulator linked to numerous cancers and other diseases.
Kymera Therapeutics Inc., a biotechnology company advancing the field of targeted protein degradation to create breakthrough therapies for previously untreatable diseases, today announced key leadership transitions
Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant B Cell Lymphoma at the 15th International Conference on Malignant Lymphoma
KYM-001 causes potent and selective IRAK4 protein knockdown and regression of OCI-LY10 tumor xenografts, both alone and in combination with BTK inhibition
Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases
Multi-year collaboration leveraging Kymera’s proprietary targeted protein degradation platform to develop novel medicines
The move by Vertex is part of the company's plan to diversify its drug discovery strategies.
Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting
Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, will present new preclinical data for its first-in-class oral IRAK4 protein degrader, KYM-001, in MYD88-mutant lymphoma
Kymera Therapeutics Announces Expansion of Scientific Advisory Board to Advance Pre-Clinical Molecules Toward the Clinic
Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, today announced the expansion of its Scientific Advisory Board (SAB) to support development of the company's Pegasus platform and advancement of its small molecule-based protein degrader therapeutics into the clinic.
Data Presented at the 2018 American Society of Hematology Annual Meeting
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, announced today that it has completed a $65 million Series B financing.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Kymera Therapeutics LLC, a biotechnology company pioneering targeted protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced the appointment of Jared Gollob, MD, to the role of Chief Medical Officer.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Collaboration to Accelerate the Discovery of Protein Degrading Therapeutics
Dr. Nuttall joins Kymera from Sanofi Genzyme where he led business development and licensing for Immunology and Inflammation and Neuroscience.